Endocrine aspects of female sexual dysfunction

Journal of Sexual Medicine

Volumn 1, Issue 1, 2004, Pages 82-86

  Davis, Susan R ^a   Guay, André T ^b   Shifren, Jan L ^c   Mazer, Norman A ^d,e  

^a MONASH UNIVERSITY   (Australia)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Watson Pharmaceuticals Inc   (United States)

^e UNIVERSITY OF UTAH   (United States)

Author keywords

Dehydroepiandrosteron therapy; Endocrine sexual dysfunction; Estrogen therapy; Hormone therapy; Progesteron therapy; Sexual desire disorder; Testosterone therapy

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CATECHOLAMINE DERIVATIVE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DOPAMINE; ESTROGEN; GLUCOCORTICOID; OXYTOCIN; PROGESTERONE; PROLACTIN; SEROTONIN; TESTOSTERONE; TIBOLONE;

ACNE; ADRENAL SUPPRESSION; ALOPECIA; AMENORRHEA; ANORGASMIA; BREAST CANCER; CLINICAL OBSERVATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG SAFETY; DYSPAREUNIA; EARLY MENOPAUSE; ESTROGEN DEFICIENCY; EVIDENCE BASED MEDICINE; FEMALE; FEMALE SEXUAL DYSFUNCTION; FOLLOW UP; HIRSUTISM; HORMONAL THERAPY; HUMAN; LIBIDO; LIBIDO DISORDER; LIVER DYSFUNCTION; MENSTRUAL CYCLE; PATIENT MONITORING; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEBORRHEA; SEXUAL AROUSAL; STANDARD; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VIRILIZATION;

EID: 15844386770     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2004.10112.x     Document Type: Article

References (8)

1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11.
2. Scarabin P-Y, Oger E, Plu-Bureau G, EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32.
3. Writing Group for Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288: 321-33.
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
5. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Caramelli KE, Mazer NA. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Eng J Med 2000;343:682-8.
6. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual function in oophorectomized women. Psychosom Med 1987;49:397-409.
7. Davis SR, McCloud PI, Strauss BJG, Burger HG. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36.
8. Modugno F, Ness R, Ewing S, Cauley J. Effects of raloxifene on sexual function in older postmenopausal women with osteoporosis. Obstet Gynecol 2003;10:353-61.